Opendata, web and dolomites

LIBSED SIGNED

Libiguins: a remedy for the treatment of sexual dysfunctions

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIBSED project word cloud

Explore the words cloud of the LIBSED project. It provides you a very rough idea of what is the project "LIBSED" about.

pe    sex    preclinical    efferents    mins    turn    pde    wants    efficacy    guide    candidate    natural    men    dicot    protocol    performed    trial    intercourse    strategies    practiced    libiguin    onset    sme    utilises    options    medicine    burden    slow    compound    tactile    standard    life    induce    planning    treatments    sexual    tackle    data    quality    afferent    ejaculation    plant    stimuli    types    commercialisation    inhibitors    cns    first    inability    serious    ethnopharmacological    exerts    billion    premature    erection    groups    worldwide    erectile    neuronal    prepare    controls    behavior    delayed    socioeconomic    date    criticism    care    implications    dic2024    visual    couple    drug    uniqueness    ethnic    promise    human    action    integration    limited    15    plan    effect    clinical    accordingly    ed    instrument    substantial    coupled    commercialization    spinal    treatment    lies    dysfunction    auditory    time    business    give    sd    integrative    supporting   

Project "LIBSED" data sheet

The following table provides information about the project.

Coordinator
DICOT AB 

Organization address
address: DAG HAMMARSKJOLDS VAG 30
city: UPPSALA
postcode: 752 37
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DICOT AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

This project will develop a business plan to guide clinical development and commercialization strategies for DIC2024, a novel drug candidate for the treatment of the common types of sexual dysfunction (SD): erectile dysfunction (ED) and premature ejaculation (PE) that affects 2 billion men worldwide. SD has serious implications on quality of life and is a significant socioeconomic burden. Current standard-of-care includes the use of PDE-5 inhibitors for ED and limited options for PE. The available treatments do not give long effect duration and therefore a major criticism is their inability to facilitate a more natural sex life that does not require planning every time a couple wants to have sexual intercourse. This is also related to delayed efficacy (15-60 mins) when using PDE-5 inhibitors. Accordingly, Dicot has developed DIC2024 that utilises a principle from a plant called Libiguin. Libiguin exerts a slow-onset, long-term action on the CNS’s integrative control systems for sexual behavior, which in turn controls spinal neuronal efferents that control erection and sexual behaviour. It also includes integration of afferent stimuli (tactile, visual, auditory). DIC2024’s uniqueness therefore lies in its potential to induce long term effects to tackle SD. The preclinical work performed to date includes development of the production protocol and studies to characterize the compound. Coupled with ethnopharmacological data (traditional medicine practiced by ethnic groups) supporting clinical use of Libiguin in men with SD, there is significant promise for the use of DIC2024 in the treatment of ED and PE. The proposed project will further prepare DIC2024 for a first-in-human clinical trial. SME Instrument funding will allow Dicot to take substantial steps along the path of commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIBSED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIBSED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More  

LTS (2020)

LEARNING TO SLEEP: INCREASING HEALTH THROUGH BETTER SLEEP

Read More